Recombinant factor VIIa is a pan-hemostatic agent?
Aledort
L M
LM
Mount Sinai Medical Center, the Mount Sinai Hospital, New York, NY 10029, USA. louis.aledort@mssm.edu
D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D016063:Blood Loss, Surgical / Q000517:prevention & control; D015942:Factor VIIa / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006490:Hemostatics / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D011183:Postoperative Complications / Q000139:chemically induced; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012449:Safety; D013915:Thrombasthenia / Q000150:complications / Q000188:drug therapy*; D013927:Thrombosis / Q000139:chemically induced
D000933:Antifibrinolytic Agents; D006490:Hemostatics; D011994:Recombinant Proteins; D015942:Factor VIIa